基于真实世界人工智能分析的脑血疏口服液治疗脑卒中的回顾性研究  

Retrospective study on Naoxueshu Oral Liquid in the treatment of stroke based on real-world artificial intelligence analysis

作　　者：李倩 郭艳[1] 徐梓铭 高翔[2] 王腾蛟[2] LI Qian;GUO Yan;XU Zi-ming;GAO Xiang;WANG Teng-jiao(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;School of Information Technology,Peking University,Beijing 100871,China)

机构地区：[1]中国中医科学院西苑医院,北京100091 [2]北京大学信息技术学院,北京100871

出　　处：《中华中医药杂志》2022年第2期1056-1061,共6页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金项目(No.81774138)。

摘　　要：目的:基于真实世界人工智能方法分析中国中医科学院西苑医院脑血疏口服液患者群,建立脑血疏口服液的用药模型,为中成药的临床适用证探索真实世界数据研究的方法。方法:筛选2006—2015年患者病历信息,纳入门诊患者13159例及住院患者1875例,通过人工智能分析方法,采用Apriori算法、R语言绘图进行描述性分析并建立使用脑血疏口服液的决策树模型。结果:使用脑血疏口服液的患者群以中老年人为主(70~79岁最多),男性(门诊占64.17%,住院占63.73%)发病率均高于女性;缺血性脑卒中(90.60%)远多于出血性脑卒中(6.22%),症状多见偏瘫、肢体力弱,辨证以痰阻、气虚、血瘀为主。住院患者的好转率约为82.03%,门诊患者复诊率为83.21%。凝血功能数据均在正常值范围内,治疗前后比较,APTT、TT、FIB有统计学意义(P<0.05),但没有明显临床意义。缺血性脑卒中及出血性脑卒中症候群均可作为脑血疏口服液用药模型;有脑梗死病史或基础疾病有高血压病也可作为脑血疏口服液预防脑卒中或再次脑卒中用药模型。结论:脑血疏口服液不仅适用于出血性脑卒中,临床更多应用于缺血性脑卒中的治疗,其治疗的脑血管疾病人群特征明确,可能因其具有双向调节作用,本研究对于脑血管疾病的预后及预防发作有积极意义。Objective: Based on the real-world artificial intelligence method, the patient group of Naoxueshu Oral Liquid in Xiyuan Hospital, China Academy of Chinese Medical Sciences was analyzed, and the medication model of Naoxueshu Oral Liquid was established to explore the real-world data research method for the study of the clinical applicability of Chinese patent medicine.Methods: The patient’s medical record information from 2006 to 2015 was screened and included in outpatient(13 159 cases) and inpatient(1 875 cases). Through artificial intelligence analysis method, Apriori algorithm and R language drawing were used for descriptive analysis, and the decision tree model of Naoxueshu Oral Liquid was established. Results: The patients in the group of mainly using the elderly people were the most elderly(70~79 years old), and the incidence rate of male(outpatient service 64.17%,hospitalization 63.73%) was higher than that of female. Ischemic stroke(90.60%) was much more than hemorrhagic stroke(6.22%).The symptoms were mostly hemiplegia and weak limb strength. The syndrome differentiation was mainly phlegm obstruction, qi deficiency and blood stasis. The improvement rate of inpatients was about 82.03%, and the follow-up rate of outpatients was 83.21%.The coagulation function data were within the normal range. APTT, TT and FIB showed statistical significance(P<0.05), with little significance. Ischemic stroke and hemorrhagic stroke syndrome could be used as drug models of Naoxueshu Oral Liquid;It could also be used as a drug-application model for Naoxueshu Oral Liquid to prevent stroke or recurrent stroke. Conclusion: Naoxueshu Oral Liquid is not only suitable for hemorrhagic stroke, but also for ischemic stroke in clinical practice. The characteristics of the population with cerebrovascular diseases treated are specific, and this study may have positive significance for the prognosis and prevention of cerebrovascular diseases due to its bidirectional regulation effect.

关 键 词：脑血疏口服液 脑卒中 人工智能 关联规则分析 用药模型 

分 类 号：R743.3[医药卫生—神经病学与精神病学]